tiprankstipranks
Pluristem Therapeutics (PSTI)
NASDAQ:PSTI

Pluristem (PSTI) Income Statement

0 Followers

Pluristem Income Statement

Last quarter (Q ), Pluristem's total revenue was $234.00K, an increase of Infinity% from the same quarter last year. In Q, Pluristem's net income was $-9.87M. See Pluristem’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 21Jun 20Jun 19Jun 18Jun 17
Total Revenue
$ 234.00K$ 0.00$ 23.00K$ 54.00K$ 50.00K$ 0.00
Cost of Revenue
-$ 0.00$ 0.00$ 2.00K$ 2.00K$ 0.00
Gross Profit
-$ 0.00$ 23.00K$ 52.00K$ 48.00K$ 0.00
Operating Expense
$ 47.53M$ 50.62M$ 29.50M$ 35.58M$ 33.78M$ 28.02M
Operating Income
$ -47.30M$ -50.62M$ -29.48M$ -35.53M$ -33.73M$ -28.02M
Net Non Operating Interest Income Expense
$ 73.00K$ 391.00K$ 352.00K$ 356.00K$ -661.00K$ -712.00K
Other Income Expense
-$ 367.00K$ -28.00K$ -131.00K$ 8.27M$ 917.00K
Pretax Income
$ -46.86M$ -49.87M$ -29.15M$ -35.31M$ -26.13M$ -27.81M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -46.80M$ -49.87M$ -29.15M$ -35.31M$ -26.13M$ -27.81M
Basic EPS
$ -1.47$ -1.77$ -1.60$ -2.90$ -2.50$ -3.20
Diluted EPS
$ -1.47$ -1.77$ -1.60$ -2.90$ -2.50$ -3.20
Basic Average Shares
$ 128.04M$ 28.11M$ 18.20M$ 12.33M$ 10.59M$ 8.74M
Diluted Average Shares
$ 128.04M$ 28.11M$ 18.20M$ 12.33M$ 10.59M$ 8.74M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 47.53M$ 50.62M$ 29.50M$ 35.59M$ 33.78M$ 28.02M
Net Income From Continuing And Discontinued Operation
$ -46.80M$ -49.87M$ -29.15M$ -35.31M$ -26.13M$ -27.81M
Normalized Income
$ -46.80M$ -50.23M$ -29.12M$ -35.18M$ -34.39M$ -28.73M
Interest Expense
$ 581.00K$ 78.00K$ 196.00K$ 0.00$ 0.00-
EBIT
$ -46.28M$ -49.79M$ -29.48M$ -35.31M$ -26.13M$ -28.02M
EBITDA
$ -45.03M$ -48.42M$ -27.91M$ -33.34M$ -24.11M$ -25.84M
Currency in USD

Pluristem Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis